Ticker

Rafael (NYSE: RFL - Get Free Report) and 60 Degrees Pharmaceuticals (NASDAQ: SXTP - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation. Profitability This table compares Rafael and 60

GoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine) Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company's marketing strategy Partnership will improve the affordability of ARAKODA at over 70,000 pharmacies nationwide for people planning travel to malaria-endemic regions WASHINGTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.…

60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) shares are set to reverse split on the morning of Tuesday, January 20th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, January 19th. 60 Degrees Pharmaceuticals Trading Down 2.4% SXTP stock opened

WASHINGTON, Jan. 15, 2026 (GLOBE NEWSWIRE) -- 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it will effect a one-for-four (1:4) reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become…

Peer-reviewed NC State study found Babesia in 24% of chronic fatigue patients, supporting further study of chronic babesiosis and ARAKODA® evaluation.